Expert Analysis

CME

Key Studies in Nonmalignant Hematology: Independent Conference Coverage of ASH 2020

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: February 11, 2021

Expiration: February 10, 2022

Hanny Al-Samkari
Hanny Al-Samkari, MD
Mark A. Schroeder
Mark A. Schroeder, MD
Sujit Sheth
Sujit Sheth, MD

Activity

Progress
1
Course Completed

At the 2020 ASH Annual Meeting, new clinical trial data in nonmalignant hematologic disorders were reported, including novel approaches in immune thrombocytopenia (ITP), hereditary blood disorders (hemophilia, sickle cell disease, and β-thalassemia), and therapies for acute or chronic graft-vs-host disease (GVHD). In this module, Hanny Al-Samkari, MD; Sujit Sheth, MD; and Mark A. Schroeder, MD, review and discuss the clinical implications of key studies in these hematologic disorders that were presented at the meeting.

Please note that the slide thumbnails in this activity link to brief PowerPoint slidesets that can also be found here, each focused on the specific study or topic of interest. These slidesets may be downloaded by clicking on any of the thumbnails within the activity.

Clinical Care Options plans to measure the educational impact of this activity. A few questions will be asked twice: once at the beginning of the activity and then once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

If you are a practicing clinician, how many patients with a nonmalignant hematologic disorder do you provide care for in a typical month?

During a consultation with a patient recently diagnosed with ITP who is considering therapeutic options, you mention the recently reported FLIGHT phase III trial that evaluated mycophenolate mofetil plus corticosteroids vs corticosteroids alone as first-line therapy in patients with ITP. In your discussion, which of the following findings would you indicate was reported with mycophenolate mofetil plus corticosteroids vs corticosteroid alone?

Based on the HOPE-B trial of etranacogene dezaparvovec gene therapy for adult patients with hemophilia B, which of the following characteristics would exclude a patient as a potential candidate for this therapy?

You recently attended the 2020 Hematology annual meeting and a colleague caring for patients with chronic GVHD asks you to share insights from the REACH3 study that compared ruxolitinib with best available therapy (BAT) in patients with steroid-refractory/dependent chronic GVHD. Which of the following results will you mention was reported from the REACH3 study?

What is the molecular target of the novel agent belumosudil that is being investigated in patients with persistent chronic GVHD?